AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review

AD Wechalekar, M Fontana, CC Quarta, M Liedtke - Cardio Oncology, 2022 - jacc.org
Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of
cardiomyopathy are common presenting features, and patients often are referred to …

[HTML][HTML] Systemic AL amyloidosis: current approach and future direction

MB Zerdan, L Nasr, F Khalid, S Allam, Y Bouferraa… - Oncotarget, 2023 - ncbi.nlm.nih.gov
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder
characterized by deposition of amyloidogenic monoclonal light chain fragments causing …

[HTML][HTML] 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis

CC Wang, WT Chang, YH Lin, BH Tzeng… - Acta Cardiologica …, 2023 - ncbi.nlm.nih.gov
Cardiac amyloidosis is one form of systemic amyloidosis caused by abnormal amyloid fibrils
deposited in the extracellular space of the myocardium causing heart failure because of …

Artificial intelligence-enhanced electrocardiogram for the diagnosis of cardiac amyloidosis: A systemic review and meta-analysis

LA Khan, FH Shaikh, MS Khan, B Zafar… - Current Problems in …, 2024 - Elsevier
Background Diagnosis of cardiac amyloidosis (CA) is often delayed due to variability in
clinical presentation. The electrocardiogram (ECG) is one of the most common and widely …

Advance of echocardiography in cardiac amyloidosis

S Liang, Z Liu, Q Li, W He, H Huang - Heart Failure Reviews, 2023 - Springer
Cardiac amyloidosis (CA) occurs when the insoluble fibrils formed by misfolded precursor
proteins deposit in cardiac tissues. The early clinical manifestations of CA are not evident …

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article

M Hussain, S Yellapragada… - Blood and Lymphatic …, 2023 - Taylor & Francis
Multiple myeloma (MM) is a hematologic malignancy characterized by the abnormal clonal
proliferation of plasma cells that may result in focal bone lesions, renal failure, anemia …

Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review

K Bay, F Gustafsson, M Maiborg… - ESC heart …, 2022 - Wiley Online Library
Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is a more common disease
than previously thought. Awareness of ATTRwt CM and its diagnosis has been challenged …

Left ventricular hypertrophy: etiology-based therapeutic options

BY Sayin, A Oto - Cardiology and therapy, 2022 - Springer
Determining the etiologies of left ventricular hypertrophy (LVH) can be challenging due to
the similarities of the different manifestations in clinical presentation and morphological …

[HTML][HTML] Transthyretin amyloid cardiomyopathy (ATTR-CM)

A Jain, F Zahra - 2021 - europepmc.org
Objectives: Summarize the epidemiology of transthyretin amyloid cardiomyopathy.. Explain
the common cardiac and non-cardiac findings associated with transthyretin amyloid …

Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution

Y Tateishi, Y Yamada, M Katsuki, T Nagata… - … -Research and Practice, 2021 - Elsevier
Aim Amyloidosis is a systemic or localized disease of protein deposition characterized by
amorphous eosinophilic morphology and positivity of Congo Red staining. The typing of …